Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort.

ABSTRACT: Voriconazole, a first-line therapy for invasive aspergillosis, carries hepatotoxicity risks lacking comprehensive epidemiological characterization. Current evidence is limited by heterogeneity in diagnostic criteria (e.g., varying thresholds for liver function abnormalities across studies), insufficient sample sizes, and inadequate adjustment for comorbidities, which compromises risk assessment accuracy. This study aims to systematically characterize the epidemiological profile of voriconazole-induced liver injury and identify modifiable independent risk factors. We analyzed 7,659 voriconazole-treated adults (2007-2020) from the First Affiliated Hospital of Zhejiang University to determine incidence and injury subtypes. Univariable and multivariable logistic regression identified risk fact

SUBMITTER: Lou Y 

PROVIDER: S-EPMC12406674 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature